|Videos|December 16, 2022

The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

Author(s)Neal Shore, MD, FACS

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

Episodes in this series

EP. 1 Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

EP. 1 Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

EP. 2 Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 2 Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 3 Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

EP. 3 Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

EP. 4 Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

EP. 4 Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

EP. 5 Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

EP. 5 Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

EP. 6 Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

EP. 6 Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

EP. 7 The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

EP. 7 The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

EP. 8 Unmet Needs and Clinical Pearls in mCRPC

EP. 8 Unmet Needs and Clinical Pearls in mCRPC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

How ARASEC and ARACOG are reshaping mCSPC treatment choices

ByUrology Times staff

August 24th 2026

Trial launches of molecular glue degrader plus apalutamide in mCRPC

ByHannah Clarke

August 24th 2026

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

ByAdam B. Weiner, MD,Tyler Seibert, MD, PhD

August 21st 2026

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

ByMary Dunn, MSN, NP-C, OCN, RN

August 20th 2026

SBRT improves multiple quality of life domains but not DFS vs MH-IMRT

ByHannah Clarke

August 18th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Trial launches of molecular glue degrader plus apalutamide in mCRPC